Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis

Balkan Med J. 2016 Nov;33(6):614-619. doi: 10.5152/balkanmedj.2016.141103. Epub 2016 Nov 1.

Abstract

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Macrophage migration inhibitory (MIF) factor is a regulatory cytokine that inhibits random immune cell migration. MIF gene promoter polymorphisms play a role in the progression of several inflammatory disorders.

Aims: To investigate the relationship between the MIF gene -173 G/C single-nucleotide polymorphism (SNP) and AS.

Study design: Cross-sectional study.

Methods: In this study, a total of 161 AS and 194 normal controls were recruited. The MIF gene -173 G/C SNP was analyzed by polymerase chain reaction using the restriction fragment length polymorphism method.

Results: There was no significant difference between groups in terms of genotype distribution (p>0.05). When wild-type G/G and G/C+C/C genotypes are compared in terms of clinical characteristics, there is a significant difference between the average age and the duration of disease in AS patients (p<0.05).

Conclusion: No significant relationship between AS disease and MIF -173 G/C polymorphism was found. MIF -173 G/C polymorphism (C allele) may affect the time of onset and the duration of disease in AS patients.

Keywords: Ankylosing spondylitis; macrophage migration inhibitory factor; polymorphism.